Related references
Note: Only part of the references are listed.Hydroxylases as therapeutic targets in inflammatory bowel disease
Eoin P. Cummins et al.
LABORATORY INVESTIGATION (2013)
Loss of Prolyl Hydroxylase-1 Protects Against Colitis Through Reduced Epithelial Cell Apoptosis and Increased Barrier Function
Murtaza M. Tambuwala et al.
GASTROENTEROLOGY (2010)
Hydroxylase Inhibition Abrogates TNF-α-Induced Intestinal Epithelial Damage by Hypoxia-Inducible Factor-1-Dependent Repression of FADD
Pieter Hindryckx et al.
JOURNAL OF IMMUNOLOGY (2010)
Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Simon A. Hirota et al.
RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY (2009)
The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis
Eoin P. Cummins et al.
GASTROENTEROLOGY (2008)
Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition
Andreas Robinson et al.
GASTROENTEROLOGY (2008)
Hypoxia and gastrointestinal disease
Cormac T. Taylor et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity
Eoin P. Cummins et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The anti-death machinery in IKK/NF-κB signaling
JL Luo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2005)
Siah2 regulates stability of prolyl-hydroxylases, controls HIF1α abundance, and modulates physiological responses to hypoxia
K Nakayama et al.
CELL (2004)
Share Paper
